This study investigates pancreatic ductal adenocarcinoma. It looks into the effects of combining an investigational medication with other treatments.
The study evaluates the safety and effects of the investigational medication when used with certain chemotherapy drugs. It examines how well the treatment works and any side effects it might have.
- Who can participate: Adults 18 years and older with pancreatic adenocarcinoma can participate. Key eligibility includes having a clinical stage IV diagnosis and meeting specific health criteria.
- Study details: Participants will receive either the investigational medication alone or combined with other treatments. Some may receive a placebo, which is an inactive substance that looks like the investigational medicine but does not contain any medicine.